Fig. 6

In vitro evaluation of anti-hAdV activities of BCV and the candidate compounds. Vero cells were infected with either hAdV C2 (a) or hAdV B21 (b) and subsequently treated with indicated concentrations of BCV or the candidate prodrugs. All compounds were tested in quadruplicate at each concentration. The solvent was used as the non-treated control. Data are presented as mean ± SD